Glaukos (GKOS) Stock Jumps After Q3 Earnings Return To Profit

Glaukos came into this Q3 2026 print with a rich growth story and a premium multiple, and the stock jumped 33.6% in a single session. The headline that drove the move was simple: the ophthalmology specialist delivered record net sales of US$211 million and reported a modest quarterly profit after losses earlier this year.

That price jump suggests elevated optimism. The income statement presents a more grounded picture in which rapid top line expansion coincides with the first signs of earnings traction after a long stretch of red ink.

Love Glaukos' surging sales and fresh profitability but concerned about paying up for a premium story without a long profit record? Check out list of solid balance sheet and fundamentals stocks (22 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$211.03 million vs. US$133.54 million (up about 58%)
• Net Income / Loss (Q3 2026 vs. Q3 2025): Net income of US$2.02 million vs. net loss of US$16.23 million (moved from loss to profit)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.03 per share vs. a loss of US$0.28 per share (returned to positive EPS)
• Trailing 12-Month Revenue (Q3 2026 TTM vs. Q3 2025 TTM): US$690.33 million vs. US$469.82 million (up about 47%)

Glaukos raised 2026 guidance and set a bold 2027 target. Ask Charlie what makes Glaukos so confident in $1B 2027 revenue.

Glaukos bull case: proof points, not just promises

The optimistic view says Glaukos can turn its glaucoma and corneal franchises into a true platform business, not just two strong launches.

"Some analysts expect Glaukos to build on iDose TR and Epioxa traction and position itself as a leading interventional ophthalmology platform company across glaucoma and corneal disease."

Q3 shows real steps in that direction. iDose TR and Epioxa together anchored record US$211 million revenue and supported non GAAP gross margin near 88%. Corneal Health reached US$59 million with broad payer access, while glaucoma delivered US$118.6 million globally. Raised 2026 guidance and a US$1b 2027 revenue goal indicate management sees these engines as durable, not one off.

Glaukos bear case: corneal transition and spend still biting

The cautionary view focuses on corneal transition risk and heavy investment that could outrun revenue.

"The planned transition in Glaukos' Corneal Health franchise, including the move from Photrexa to Epioxa and the implementation of a permanent J code, is expected to create a temporary air pocket in revenues around Q3 2026."

Instead of a visible hole, Epioxa drove about US$53 million in its first meaningful J code quarter, and Corneal Health posted record sales. The concern on spending is more visible. Operating expenses are guided to about US$630 million for 2026, roughly 30% higher than 2025, and management flags another step up in Q4, so operating leverage remains a work in progress despite Q3 profitability.

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for.

Hunt Quiet Mispricings Now

Glaukos just showed how quickly sentiment can reset when a story finally prints clean numbers. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 46% below our estimate - turns an AI-driven recommendation engine into a system that predicts what users will buy next and sells targeted advertising against those signals.
• Company 2 - 43% below our estimate - expands payment rails that let large online platforms move money in and out of fast-growing local methods through one integrated stack.
• Company 3 - 36% below our estimate - builds a recommerce network that collects used devices, refurbishes them efficiently, and channels demand for subsidised trade ins and secondhand upgrades.

Those are three of them. See all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com